Document is current
Any future updates will be listed below
-
Authors
Cerezuela-Fuentes, Pablo https://orcid.org/0000-0002-4886-4831
Piñero-Madrona, Antonio
Muñoz-Couselo, Eva
Manzano, José Luis
Berciano-Guerrero, Miguel-Ángel
Majem, Margarita
Espinosa, Enrique
Soria, Ainara
Ayala de Miguel, Pablo
García Castaño, Almudena
Crespo, Guillermo
Gutiérrez Sanz, Lourdes
Aguado de la Rosa, Carlos
Fernández-Morales, Luis Antonio
Puértolas, Teresa
Fra Rodríguez, Joaquín
Rodríguez de la Borbolla, María
Bellido, Lorena
López Castro, Rafael
Navarro Pérez, Victor
García Arroyo, Francisco Ramón
Villa Guzmán, José Carlos
Campos Balea, Begoña
Hernández, Berta
Martín Algarra, Salvador
Márquez-Rodas, Iván
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03605771 at ClinicalTrials.govDocuments that mention this clinical trial
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.
https://doi.org/10.1200/jco.2023.41.16_suppl.9547
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801
https://doi.org/10.1007/s12094-025-04098-3
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801
https://doi.org/10.1007/s12094-025-04164-w
Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801.
https://doi.org/10.1200/jco.2024.42.16_suppl.e21515
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)
https://doi.org/10.1007/s12094-025-04005-w
- License Information
-
More Information
Article History
Received: 6 July 2025
Accepted: 25 November 2025
First Online: 20 December 2025
Declarations
:
: PC-F declares: consulting fees BMS, MSD, Novartis, Pierre Fabre. IMR declares Advisory role: Amgen, Astra Zeneca, BiolineRx, BMS, Celegene, GSK, Highlight Therapeutics, Immunocore, Merck Serono, MSD, Novartis, Pierre Fabre, Regeneron, Roche, Sanofi, Sun Pharma and Travel accommodation and congress: Amgen, BMS, GSK, Highlight Therapeutics, MSD, Novartis, Pierre Fabre, Roche, Sun Pharma. EMC declares Consultant or Advisory Role: Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Regeneron; Research Funding. MSD, Sanofi, BMS; Speaking: Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Regeneron; Clinical trial participation (principal investigator): Amgen, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Replimune, Iovance, Bioinvent. BCB declares Advisory role: Astra Zeneca, Roche, BeiGene; Speaking: Astra Zeneca, Roche, MSD, Rovi, Sun Pharma, Novartis, Pierre Fabre, BMS, Inmunocore; and Travel accommodation and congress: BMS, Pierre Fabre, Roche, Astra Zeneca, Rovi. LBH declares speaker fees from Astra Zeneca, Amgen, Pierre Fabre, Janssen; and support for attending meetings from MSD, Novartis, Sanofi, Astra Zeneca, Roche, Pierre Fabre, Pfeizer.
: Patient data will be provided upon reasonable request. Any request should be sent to the corresponding author with a detailed description of the research protocol. The Sponsor reserves the right to decide whether to share the data or not. Access will be provided to the data after the proposal has been approved by an independent review committee established for this purpose.
